Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - beclometasone dipropionate - inhalation powder - 100microgram

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - salbutamol sulfate - inhalation powder - 400microgram

Güney Afrika - İngilizce - South African Health Products Regulatory Authority (SAHPRA)

sekpharma (pty) ltd - inhaler - each capsule contains beclomethasone dipropionate equivalent to beclomethasone 100,0 ug

Güney Afrika - İngilizce - South African Health Products Regulatory Authority (SAHPRA)

sekpharma (pty) ltd - inhaler - each capsule contains beclomethasone dipropionate equivalent to beclomethasone 200,0 ug

Ürdün - İngilizce - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - salbutamol 200 mcg - 200 mcg

Ürdün - İngilizce - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - salbutamol 400 mcg - 400 mcg

Namibya - İngilizce - Namibia Medicines Regulatory Council

glaxosmithkline south africa (pty) ltd - salbutamol sulphate - inhalation powder in hard capsule - each rotacap contains salbutamol sulphate 200 mcg

ABD - İngilizce - NLM (National Library of Medicine)

laboratoire français du fractionnement et des biotechnologies société anonyme (lfb s.a.) - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - sevenfact  [coagulation factor viia (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia a or b with inhibitors.  limitation of use: sevenfact is not indicated for the treatment of patients with congenital factor vii deficiency. sevenfact is contraindicated in - known allergy to rabbits or rabbit proteins. exposure to sevenfact in these patients can result in severe hypersensitivity reaction.  - patients with severe hypersensitivity reaction to sevenfact or any of its components. exposure to sevenfact in these patients can result in severe hypersensitivity reaction.  risk summary there are no adequate and well-controlled studies using sevenfact in pregnant women to determine whether there is a drug-associated risk. animal studies evaluating the embryo-fetal teratogenic potential of sevenfact have not been conducted. it is unknown whether sevenfact can cause fetal harm when administered to a pregnant

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i.e. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu

Birleşik Arap Emirlikleri - İngilizce - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

common fennel (foeniculum vulgare mill) seed dry extract (10% flavonoids), indian senna (cassia angustifolia vahl) leaves dry extract (20% sennosides), european alder buckthorn (rhamnus frangula mill.) barks of stem and branches dry extract (15% of glucofrangulin), sorrel rhubarb (rheum palmatum l) root dry extract (4.5% hydroxyanthracene derivates) -